MBMorten Rune Blichfeldt-Eckhardt

Morten Rune Blichfeldt-Eckhardt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Morten Rune Blichfeldt-Eckhardt has a total of 117 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Age-specific upper reference limits for Simoa-measured cerebrospinal fluid glial fibrillary acidic protein: a cross-sectional DANPAIN biobank study

    by Lasse M. Obel, Michael W. Hunderup, Jonna S. Madsen, Eva R. B. Petersen, Dorte A. Olsen, Jakob L. Wetche, Kate L. Lambertsen, Morten Blichfeldt-Eckhardt

  • Open Access

    Management of Pain in the Intensive Care Unit: A Nordic Survey

    by Benedikte Kollerup Madsen, Morten Hylander Møller, Stine Estrup, Lone Musaeus Poulsen, Bodil Steen Rasmussen, Kirstine Sylvester Conradsen, Thomas Lass Klitgaard, Asger Granfeldt, Theis Skovsgaard Itenov, Hans Christian Thorsen Meyer, et al.

    Background: Pain is common in intensive care unit (ICU) patients with up to one‐third experiencing pain at rest and even more during mobilization and clinical procedures. This survey aimed to explore physicians' attitudes and preferences regarding pain management in adult ICU patients in the Nordic countries. Methods: We conducted an electronic survey targeting physicians working regularly in an ICU in the Nordic countries: Denmark, Finland, Iceland, Norway and Sweden. The survey focused on pain assessment, pharmacological treatments, and post‐discharge follow‐up of adult ICU patients. Results: The survey was distributed to 606 physicians, and 360 responses were received (overall response rate 59%). Respondents were primarily from Denmark, with only a few respondents from the remaining Nordic countries. Most respondents were specialists in anesthesiology working in mixed ICUs in public specialist hospitals. Standardized pain assessment tools were widely used in non‐sedated patients, while only half of respondents employed standardized pain assessment tools in sedated patients. Respondents reported that pain was assessed multiple times daily in both non‐sedated and sedated patients. Daily wake‐up calls in sedated patients were considered important by almost all respondents. Morphine was the preferred opioid for oral‐ and intravenous bolus administration, while remifentanil was preferred for intravenous continuous administration. However, preferences varied across countries with regard to both opioid‐ and non‐opioid analgesics. Nearly half of respondents expressed concerns regarding the development of opioid‐induced hyperalgesia. Methadone was the most frequently preferred drug for opioid weaning, although preferences varied between countries. Most respondents acknowledged the importance of ICU‐follow up programs, but only about half of respondents reported that their ICU currently offered a follow‐up service. Conclusion: This Nordic survey explored ICU physicians' attitudes and preferences regarding pain management in adult ICU patients. Respondents reported assessing pain frequently, employing standardized pain assessment tools primarily in non‐sedated patients. Daily wake‐up calls in sedated patients were generally perceived as important. Interestingly, preferences regarding opioid‐ and non‐opioid analgesics varied between Nordic countries. ICU‐follow up programs were recognized as important but were not consistently implemented. Despite a high overall response rate, the generalizability of our findings is impaired by limited participation in most Nordic countries except Denmark. Editorial Comment: This survey describes the physician perspective on predominantly pharmacological pain management in selected ICUs within the Nordic countries.

  • Open Access

    Low-dose naltrexone for fibromyalgia: a re-analysis suggests lower efficacy than previously reported

    by Karin Due Bruun, Maria Juul Nielsen, Henrik Bjarke Vaegter, Morten Rune Blichfeldt-Eckhardt, Kirstine Amris, Julie Roenne Pedersen

    Karin Due Bruun, Maria Juul Nielsen, Henrik Bjarke Vaegter, Morten Rune Blichfeldt-Eckhardt, Kirstine Amris, and Julie Roenne Pedersen. Korean J Pain 2026;39:140-3. https://doi.org/10.3344/kjp.25275


  • A Systematic Review With Meta‐Analysis of Endogenous Opioid System Biomarkers in Patients With Chronic Axial Pain, Chronic Widespread Pain, and Fibromyalgia

    by Karin Due Bruun, Maria Charlotte Reiersoel Moerkeberg, Julie Roenne Pedersen, Daniel Broholm, Morten Rune Blichfeldt‐Eckhardt, Lotte Abildgren

    Background: The opioid system is involved in the regulation of pain as well as stress homeostasis. Stress‐induced opioid dysregulation has been proposed as a mechanism for pain development in patients with fibromyalgia (FM) and chronic low back pain (cLBP). However, the evidence to support this hypothesis is conflicting. Methods: We conducted a systematic literature search in MEDLINE, EMBASE, and the Cochrane Library database to investigate whether patients with FM or cLBP exhibit (1) different levels of endogenous opioids or anti‐opioids in body fluids or tissue samples, or (2) altered levels of opioid receptor expression or availability compared to pain‐free controls. Results: We identified 33 studies eligible for inclusion in the review, investigating 863 patients and 636 pain‐free controls. Three meta‐analyses of beta‐endorphin levels in blood and cerebrospinal fluid (CSF) were performed, revealing no significant differences between patients with FM or cLBP and controls. However, the grading of the evidence was very low. Mu‐opioid receptor (MOR) dysfunction emerged as a potential feature of FM, with some evidence suggesting reduced MOR binding in the brain and decreased MOR expression in immune cells. Conclusions: Current evidence does not support altered peripheral endorphin levels in FM or cLBP, while emerging PET findings indicate reduced central MOR availability in FM. These results suggest receptor‐level dysregulation rather than peripheral opioid deficits. Limitations mainly arose from low sample sizes and inadequate study methodologies, underscoring the need for well‐designed studies with larger sample sizes to clarify the role of endogenous opioid dysfunction in FM and cLBP. Significance: This systematic review highlights emerging evidence of mu‐opioid receptor dysfunction in fibromyalgia, despite no consistent differences in beta‐endorphin levels. The findings underscore significant methodological limitations in existing studies and point to the need for rigorous, well‐powered research to clarify the role of endogenous opioid dysregulation in chronic pain.


  • Open Access

    Effect of Naltrexone on Spinal and Supraspinal Pain Mechanisms and Functional Capacity in Women with Fibromyalgia: Exploratory Outcomes from the Randomized Placebo-Controlled FINAL Trial

    by Karin Due Bruun, Robin Christensen, Kirstine Amris, Morten Rune Blichfeldt-Eckhardt, Lars Bye-Møller, Marius Henriksen, Tine Alkjaer, Palle Toft, Anders Holsgaard-Larsen, Henrik Bjarke Vaegter

    Background The widespread pain and muscular fatigue characteristics of fibromyalgia are believed to be mediated by central mechanisms. Low-dose naltrexone (LDN) has emerged as a new treatment option for fibromyalgia, possibly modulating central mechanisms via glial or opioid receptors. Methods In the randomized, placebo-controlled FINAL trial, 99 women with fibromyalgia were treated with LDN or placebo for 12 weeks. In this secondary analysis, we examined the potential effects of LDN versus placebo on changes from baseline in pain tolerance, temporal summation of pain, and conditioned pain modulation (CPM) in the complete case population (45 versus 47 participants). Measures of muscular fatigue were evaluated using the 30-s chair stand test and a shoulder abduction test. Results Of the five examined outcomes, only change in CPM showed a significant between-group difference with greater enhancement following LDN treatment (2.0 kPa; 95% confidence interval (CI) 0.4–3.7 kPa) compared with placebo. Within-group changes in CPM showed an increase of 1.2 kPa (95% CI 0.05–2.4 kPa) in the LDN group and a possible decrease of 0.8 kPa (95% CI − 1.9 to 0.4 kPa) in the placebo group. Conclusions We found a significant between-group difference in CPM change in favor of LDN. However, this difference was partly explained by a decrease in CPM in the placebo group. Sensitivity analyses showed no association between changes in CPM and clinical pain improvement, suggesting that the group-difference in CPM is a random finding. Study Registration ClinicalTrials.gov (NCT0427877; registered on 30 January 2020).


  • Open Access

    Efficacy of Cryoneurolysis on Chronic Pain in Patients with Knee Osteoarthritis: A Double-blinded Randomized Controlled Sham Trial

    by Niels-Peter Brøchner Nygaard, Carsten Koch-Jensen, Henrik Bjarke Vaegter, Niels Wedderkopp, Morten Blichfeldt-Eckhardt, Bibi Gram

    Background: The objective was to investigate whether cryoneurolysis was superior to sham in reducing pain intensity in patients with chronic knee osteoarthritis. The hypothesis was that cryoneurolysis is an effective and safe therapy to reduce chronic pain in patients with knee osteoarthritis. Methods: The study was randomized, double blind, and sham controlled. A total of 87 patients with chronic knee osteoarthritis were randomized to either cryoneurolysis or a sham procedure, followed by an exercise program. The target nerves, anterior femoral cutaneous nerve and infrapatellar branch of the saphenous nerve were identified using transcutaneous electrical nerve stimulation, and cryoneurolysis was performed with ultrasound guidance. The primary outcome was the difference in average pain at 14 days after intervention between the cryoneurolysis and sham group. Results: For the intention-to-treat analysis, no difference was observed for the primary outcome (0.49; 95% CI, –0.3 to 1.2; P = 0.198). Both groups showed a significant reduction in pain scores 14 days after intervention (cryoneurolysis: –1.9; 95% CI, –2.4 to –1.3; and sham: –1.4; 95% CI, –1.9 to –0.8). At 6-month follow-up, a significant reduction in pain was observed in the cryoneurolysis group compared to the sham group (1.1; 95% CI, 0.3 to 1.9; P = 0.009). Cryoneurolysis was well tolerated, with minor, transient adverse effects. Conclusions: This study did not show a clinically relevant reduction in pain after intervention comparing cryoneurolysis and sham. Further studies are needed.


  • Open Access

    Low-grade systemic inflammation, but not neuroinflammation, is associated with 12-month postoperative outcome after total hip arthroplasty in patients with painful osteoarthritis

    by Morten R. Blichfeldt-Eckhardt, Claus Varnum, Jørgen T. Lauridsen, Lasse E. Rasmussen, Winnie C. P. Mortensen, Hanne I. Jensen, Henrik B. Vaegter, Kate L. Lambertsen

    Aims: Better prediction of outcome after total hip arthroplasty (THA) is warranted. Systemic inflammation and central neuroinflammation are possibly involved in progression of osteoarthritis and pain. We explored whether inflammatory biomarkers in blood and cerebrospinal fluid (CSF) were associated with clinical outcome, and baseline pain or disability, 12 months after THA.Methods: A total of 50 patients from the Danish Pain Research Biobank (DANPAIN-Biobank) between January and June 2018 were included. Postoperative outcome was assessed as change in Oxford Hip Score (OHS) from baseline to 12 months after THA, pain was assessed on a numerical rating scale, and disability using the Pain Disability Index. Multiple regression models for each clinical outcome were included for biomarkers in blood and CSF, respectively, including age, sex, BMI, and Kellgren-Lawrence score.Results: Change in OHS was associated with blood concentrations of tumour necrosis factor (TNF), interleukin-8 (IL-8), interleukin-6 receptor (IL-6R), glycoprotein 130 (gp130), and IL-1β (R2 = 0.28, p = 0.006), but not with CSF biomarkers. Baseline pain was associated with blood concentrations of lymphotoxin alpha (LTα), TNFR1, TNFR2, and IL-6R (R2 = 0.37, p < 0.001) and CSF concentrations of TNFR1, TNFR2, IL-6, IL-6R, and IL-1Ra (R2 = 0.40, p = 0.001). Baseline disability was associated with blood concentrations of TNF, LTα, IL-8, IL-6, and IL-1α (R2 = 0.53, p < 0.001) and CSF concentrations of gp130, TNF, and IL-1β (R2 = 0.26, p = 0.002). Thus, preoperative systemic low-grade inflammation predicted 12-month postoperative outcome after THA, and was associated with preoperative pain and disability.Conclusion: This study highlights the importance of systemic inflammation in osteoarthritis, and presents a possible path for better patient selection for THA in the future. Preoperative central neuroinflammation was associated with preoperative pain and disability, but not change in OHS after THA.Cite this article: Bone Joint Res 2024;13(12):741–749.


  • Open Access

    Validation of the Danish Version of the Fibromyalgia Impact Questionnaire Revised

    by Simon Stockmann Poulsen, Hanne Irene Jensen, Karin Due Bruun, Morten Rune Blichfeldt-Eckhardt, Nina Kvorning

    Purpose: Increasing recognition of chronic pain diseases, including Fibromyalgia, warrants the need for tools to monitor the impact of the disease as well as the efficacy of interventions. The Revised Fibromyalgia Impact Questionnaire (FIQR) has previously proved to be a valuable tool in both clinical and research settings. The study objective was to translate and validate the FIQR in Danish. Patients and Methods: A forward/backward translation, following the WHO-guidelines, was used to develop the Danish version of FIQR. The Danish translation of FIQR was answered by 101 patients suffering from fibromyalgia. The patients simultaneously answered the Hospital Anxiety and Depression Scale (HADS) and the 36-Item Short-Form Health Survey (SF-36) for validation. Results: The Danish FIQR showed excellent internal consistency, and reliability with Interclass Correlation Coefficients above 0.9. The correlations to HADS and SF-36 ranged from fair to very good. All results were found to have a p-value < 0.05. Conclusion: The present version of the Danish FIQR presents a valid and reliable tool for monitoring the impact of fibromyalgia.


  • Open Access

    Examining the Duration of Carryover Effect in Patients With Chronic Pain Treated With Spinal Cord Stimulation (EChO Study): An Open, Interventional, Investigator-Initiated, International Multicenter Study

    by Kaare Meier, Cecile C. de Vos, Martine Bordeleau, Sharon van der Tuin, Bart Billet, Thomas Ruland, Morten Rune Blichfeldt-Eckhardt, Matthias Winkelmüller, Helga Angela Gulisano, Kliment Gatzinsky, et al.


  • Open Access

    The Danish Pain Research Biobank (DANPAIN-Biobank): a collection of blood, cerebrospinal fluid, and clinical data for the study of neuroimmune and glia-related biomarkers of chronic pain

    by Morten Rune Blichfeldt-Eckhardt, Winnie Charlotte Pedersen Mortensen, Claus Varnum, Laila Bendix, Jørgen Trankjær Lauridsen, Hanne Irene Jensen, Lasse Enkebølle Rasmussen, Helle Hvilsted Nielsen, Palle Toft, Kate Lykke Lambertsen, et al.

    Background: Chronic pain is a major health problem worldwide but the limited knowledge of its underlying pathophysiology impairs the opportunities for diagnostics and treatment. Biomarkers of chronic pain are greatly needed to understand the disease and develop new targets for interventions and drug treatments, and potentially introduce more precise diagnostic procedures. Much evidence points to a neuroimmune pathology for many chronic pain conditions and that important neuroimmune biomarkers exist in the cerebrospinal fluid (CSF) of patients with chronic pain. Systematic collection of CSF in large cohorts of chronic pain patients and healthy volunteers has proven difficult, however. We established the Danish Pain Research Biobank (DANPAIN-Biobank) with the aim of studying potential neuroimmune and glia-related biomarkers of chronic pain. In this paper, we describe the methods and the study population of the DANPAIN-Biobank. Methods: In this cross-sectional study, we included (I) participants with high-impact (HI) chronic pain from a tertiary, interdisciplinary pain center; (II) participants with osteoarthritic pain scheduled for arthroplasty surgery of the hip or knee at a regional hospital; and (III) pain-free volunteers. All participants completed a questionnaire assessing pain, functional impairment, anxiety, depression, and insomnia before samples of blood and CSF were extracted. Quantitative sensory tests were performed on participants with HI chronic pain and pain-free volunteers, and postoperative outcome scores were available on participants with osteoarthritic pain. Results: Of the 352 participants included, 201 had HI chronic pain (of which 71% had chronic widespread pain), 81 had chronic osteoarthritic pain, and 70 were pain-free volunteers. Samples were handled uniformly, and CSF samples were frozen within 30 minutes. Conclusions: We describe the content of the DANPAIN-Biobank, which is unique in terms of the number of participants (including pain-free volunteers), extensive clinical data, and uniformity in sample handling. We believe it presents a promising new platform for the study of neuroimmune and glia-related biomarkers of chronic pain.